Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates. Discover ESMO's new social media dashboard where you will find all your favourite posts and tweets in one place! ESMO40 Celebrate with us: watch our anniversary videos, take a virtual stroll through our timeline of 'ESMO firsts' or share your wishes for the future with us….
Secondary efficacy endpoints of disease-free survival and distant recurrence—free interval also demonstrated clinically meaningful improvements with T-DMI. Patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy have a high risk of recurrence and death. The current standard of care for these patients is continuation of the same HER2-targeted therapy in the adjuvant setting for 1 year.
Neoadjuvant chemotherapy refers to medicines that are administered before surgery for the treatment of breast cancer. Your doctors may recommend neoadjuvant chemotherapy due to the size of the tumor, since the drugs may shrink the tumor and give you more surgical options. In some cases, a woman who would have needed a mastectomy due to the large size of her tumor can become a candidate for lumpectomy by shrinking the invasive tumor prior to surgery.
All available guidelines for this clinical area are available under the "Select a Guideline" heading. To access a specific guideline, simply click on the title. You may also use the integrated search bar to find guidelines that match your search term. Simply start typing in the search field, and the list of guidelines will filter automatically to display relevant results.
Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment in the first 30 days after surgery, according to a retrospective study presented at the San Antonio Breast Cancer Symposiumheld Dec. Others recommend starting as soon as clinically possible within 31 days of surgery, however, the optimal time to initiate chemotherapy is unknown. Morante and colleagues found that patients who delayed starting adjuvant chemotherapy for more than 30 days after surgery had a more than 90 percent increased risk for disease recurrence and death compared with those who started the treatment in the first 30 days after surgery.
This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 HER2 therapies in patients with HER2-positive metastatic breast cancer MBC. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences.
Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.
Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates.
The impact of adjuvant chemotherapy on breast cancer prognosis has been demonstrated in randomized trials, but its impact is unknown in real-world populations. The aim of this study was to evaluate the effect of adjuvant chemotherapy on the survival of breast cancer patients in an unselected population. This prospective cohort study included 32, women treated at the Institut Curie between and for a first invasive breast cancer without metastasis.
How relevant the Nala data are in the real world is a separate question, however. Still, US approval is not out of the question. Nala had been run under a special protocol assessment, implying that the FDA supported its analysis plan, under which a win on either the PFS or the OS co-primary endpoint would have deemed the result positive.